NEW YORK (360Dx) – BioMérieux said today that the US Food and Drug Administration has provided clearance for the expanded use of the firm's Vidas Brahms PCT Assay, an automated test that measures levels of procalcitonin, to aid clinical decisions about the optimal use of antibiotics in patients with lower respiratory tract infections or sepsis. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.